4,720 Shares in Haemonetics Co. (NYSE:HAE) Acquired by Dark Forest Capital Management LP

Dark Forest Capital Management LP acquired a new position in shares of Haemonetics Co. (NYSE:HAE) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 4,720 shares of the medical instruments supplier’s stock, valued at approximately $369,000.

A number of other institutional investors also recently bought and sold shares of the company. Norges Bank acquired a new position in shares of Haemonetics during the 4th quarter worth $32,803,000. Groupama Asset Managment acquired a new stake in shares of Haemonetics in the fourth quarter valued at approximately $19,520,000. Raymond James Financial Inc. purchased a new position in shares of Haemonetics during the 4th quarter worth approximately $19,002,000. Thrivent Financial for Lutherans raised its position in shares of Haemonetics by 14.9% during the 4th quarter. Thrivent Financial for Lutherans now owns 1,264,294 shares of the medical instruments supplier’s stock worth $98,716,000 after purchasing an additional 164,111 shares during the last quarter. Finally, Boston Partners lifted its stake in Haemonetics by 27.5% in the 4th quarter. Boston Partners now owns 536,262 shares of the medical instruments supplier’s stock valued at $41,485,000 after buying an additional 115,506 shares in the last quarter. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms have weighed in on HAE. StockNews.com downgraded Haemonetics from a “buy” rating to a “hold” rating in a research report on Saturday, February 15th. JMP Securities dropped their price objective on Haemonetics from $125.00 to $100.00 and set a “market outperform” rating for the company in a research report on Friday, February 7th. Bank of America lowered shares of Haemonetics from a “neutral” rating to an “underperform” rating and reduced their target price for the company from $95.00 to $68.00 in a report on Friday, February 7th. Raymond James reissued a “strong-buy” rating and issued a $115.00 price objective (down previously from $120.00) on shares of Haemonetics in a research report on Friday, February 7th. Finally, Needham & Company LLC decreased their target price on shares of Haemonetics from $108.00 to $104.00 and set a “buy” rating on the stock in a research report on Tuesday, March 18th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $101.22.

Haemonetics Stock Performance

Shares of HAE stock opened at $62.53 on Monday. The company has a debt-to-equity ratio of 1.35, a quick ratio of 2.55 and a current ratio of 3.97. The firm has a market capitalization of $3.14 billion, a price-to-earnings ratio of 24.62, a price-to-earnings-growth ratio of 1.11 and a beta of 0.41. Haemonetics Co. has a one year low of $55.30 and a one year high of $97.97. The company has a 50 day moving average price of $62.83 and a 200 day moving average price of $72.11.

Haemonetics (NYSE:HAE) last announced its quarterly earnings data on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.20 by ($0.01). Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. Sell-side analysts anticipate that Haemonetics Co. will post 4.55 EPS for the current year.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.